Applied genetic technologies.

Applied Genetic Technologies Corporation (AGTC) is developing a recombinant adeno-associated virus (rAAV) vector AGTC-501, also designated rAAV2tYF-GRK1-hRPGRco, to treat X-linked retinitis pigmentosa (XLRP) in patients with mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene.The vector contains a codon-optimized …Beacon Therapeutics Holdings’ XLPR candidate is AGTC-501, an adeno-associated virus (AAV)-based gene therapy which had been developed and shepherded through an earlier clinical study by Applied ...President and Chief Executive Officer, Applied Genetic Technologies Corporation November 3, 2022. About AGTC. AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.Oct 24, 2022 · Syncona to Acquire Applied Genetic Technologies Corporation. Upfront consideration in cash of $0.34 per share representing a premium of approximately 42% over AGTC’s closing stock price on ...

Track Applied Genetic Technologies Corp (AGTC) Stock Price, Quote, latest community messages, chart, news and other stock related information.30 thg 11, 2022 ... Acompanhe a ação AGTC (Applied Genetic Technologies Corp.): gráficos, cotações, notícias e mais.

Metabolic diseases include a group of syndromes that are caused by both genetic factors and the environment. 100 Gene editing technology can be applied in functional gene screening, gene therapy ...TipRanks | Stock Market Research, News and Analyst Forecasts ...

Dec 1, 2022 · Applied Genetic Technologies Corporation (AGTC) · Syncona to invest $23.3 million upfront to acquire AGTC. · AGTC to become Syncona's third retinal gene therapy company, focused on driving AGTC-501, for X-linked retinitis pigmentosa, through late-stage clinical development. The Applied Genetic Technologies Corporation is a publicly traded (Nasdaq: AGTC) biotechnology company that is part of the NASDAQ Biotechnology Index. It was founded in 1999 and has its headquarters in Alachua, Florida. In late June 2019, the company announced the appointment of Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah, M.D., M.B.A., to Join as Chief Medical Of…Applied Genetic Technologies Corporation (the “Company”) from time to time presents at various industry and other conferences a summary of recent corporate and clinical developments. A copy of the slide presentation that will be used by officers of the Company in connection with such presentations (the “Corporate Presentation”) is attached to this …Zenglu Li Georgia Seed Development Professor in Soybean Breeding and Genetics Crop & Soil Sciences Institute of Plant Breeding, Genetics and Genomics (IPBGG) Contact Information [email protected] 706-542-9805 706-542-0914. Mailing Address Athens, CAES Campus Center for Applied Genetic Technologies, 111 Riverbend Road, Athens, GA …Follow. Dublin, June 28, 2021 (GLOBE NEWSWIRE) -- The "Gene Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The ...

Applied Genetic Technologies Corporation is developing rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus (rAAV) vector for treatment of X-linked retinoschisis (XLRS), an inherited retinal disease characterized by splitting (schisis) of retinal layers causing poor vision. We report here results …

Prior to joining Cytovia, he was Chief Financial Officer and Treasurer at Applied Genetic Technologies Corporation (AGTC), a publicly traded gene therapy company, where he led multiple financings ...

Melissa G Mitchum Professor, Plant Nematology Plant Pathology Center for Applied Genetic Technologies (CAGT) Institute of Plant Breeding, Genetics and Genomics (IPBGG) Contact Information [email protected] 706-542-6347. Mailing Address Athens, CAES Campus 111 Riverbend Rd, Rm 211, Athens, GA 30602. Shipping …To facilitate your analysis, this report presents a range of insights extracted from the decade-long performance of Applied Genetic Technologies Corporation ( ...In recent years, a number of biotechnology companies have applied genetic-information-driven technologies to form “biomolecular platforms” (exhibit). These platforms intervene at different points in the information chain (often referred to as “the central dogma of biology”) to modify biomolecular processes at the source of various diseases. ... The …AGTC | 6,533 followers on LinkedIn. Visionary science for life-changing cures. | AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products ...Applied Genetic Technologies Corporation (NASDAQ:AGTC) Q3 2021 Earnings Conference Call May 17, 2021 4:30 PM ETCompany Participants. Sue Washer – President and Chief Executive Officer. Stephen ... Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients ... Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is on the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP ...

Applied Genetic Technologies Corporate Headquarters, Office Locations and Addresses | Craft.co.AGTC and Otonomy each disclaim any obligation to update any forward-looking statements, except as required by law. AGTC Contacts: IR/PR Contacts: David Carey (IR) or Tom Vickery (PR) Lazar ...Historical daily share price chart and data for Applied Genetic Technologies from 2014 to 2022 adjusted for splits and dividends.Apr 13, 2021 · Applied Genetic Technologies Corporation T: (617) 413-2754 [email protected] ... Applied Genetic Technologies Corporation ( NASDAQ: AGTC) is a nanocap developing gene therapies for rare diseases. Its lead indication is XLRP, or X-Linked Retinitis Pigmentosa, a relatively rare ...Oct 24, 2022 · These now include Applied Genetic Technologies Corp., which, rather than face the “challenging” funding environment ahead, has opted for a $23.5 million sale to investment fund Syncona. AGTC ... Applied Genetic Technologies Corporation October 23, 2022 at 7:05 PM · 10 min read Upfront consideration in cash of $0.34 per share representing a premium of approximately 42% over AGTC’s ...

Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients ... Applied Genetic Technologies Corporation. T: (617) 843-5728. [email protected]. Stephen Potter. Chief Business Officer. Applied Genetic Technologies Corporation. T: (617) 413-2754. spotter@agtc ...

On January 11, 2022, Applied Genetic Technologies Corporation issued a press release announcing updated information regarding its ongoing X-linked retinitis pigmentosa (XLRP) clinical trials. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.Beacon Therapeutics is an ophthalmic gene therapy company founded to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that …Applied Genetic Technologies Corporation Under the 2013 Equity and Incentive Plan Applied Genetic Technologies Corporation (the “Company”) hereby grants to the person named below (the “Recipient”) restricted stock units (“Restricted Stock Units”), with each such unit representing the right to receive one share of Stock, pursuant to the terms set …13 thg 12, 2018 ... Gainesville, Florida-based Applied Genetic Technologies Corporation, also known as AGTC, said Wednesday that topline interim data from its ...Jun 13, 2023 · Beacon Therapeutics has kickstarted its entry into the gene therapy field with a $120m Series A financing. The British investment trust Syncona Limited launched the new ophthalmic gene therapy company by combining Applied Genetic Technologies Corporation’s (AGTC’s) late-stage X-linked retinitis pigmentosa (XLRP) programme with two ... Dec 1, 2022 · GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today the successful ... RTGN. --RetinalGeniX Technologies Inc., today announced that Dessislava Boneva, M.D. has joined the Company’ s Board of Directors.. RetinalGeniX is an …Applied Genetic Technologies Corporation ( NASDAQ: AGTC) is a nanocap developing gene therapies for rare diseases. Its lead indication is XLRP, or X-Linked Retinitis Pigmentosa, a relatively rare ...Nov 14, 2022 · GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, sent the ... Oct 24, 2022 · Applied Genetic Technologies Corporation, a Cambridge- and Florida-based gene therapy firm better known as AGTC could go private through an acquisition by a Floridian investment firm.

Oct 25, 2022 · The tender offer is approximately $23.5 million in cash ($0.34 per share). If completed, the acquisition – which has been termed a “low ball bid” by some – of AGTC will become Syncona’s ...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today that a ...

Prior to joining Cytovia, he was Chief Financial Officer and Treasurer at Applied Genetic Technologies Corporation (AGTC), a publicly traded gene therapy company, where he led multiple financings ...Applied Genetic Technologies Corporation T: 617-413-2754 [email protected] ...30 thg 11, 2022 ... Acompanhe a ação AGTC (Applied Genetic Technologies Corp.): gráficos, cotações, notícias e mais.GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of ...Prior to joining Cytovia, he was Chief Financial Officer and Treasurer at Applied Genetic Technologies Corporation (AGTC), a publicly traded gene therapy company, where he led multiple financings ...GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of ...Applied Genetic Technologies Corp. is being taken private by healthcare company creator Syncona in a transaction that will keep the struggling gene therapy developer from running out of cash next year. Syncona will pay $0.34 per share, or about $23.5 million, for rights to the company, which is commonly known as AGTC.GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of ...Applied Genetic Technologies Corporation (Exact name of registrant as specified in its charter) Applied Genetic Technologies Corporation . 14193 NW 119th Terrace . Suite 10 . Alachua, Florida, 32165 (386) 462-2204 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

APPLIED GENETIC TECHNOLOGIES CORP (Filer) CIK: 0001273636 (see all company filings) IRS No.: 593553710 | State of Incorp.:DE | Fiscal Year End: 0630 Type: 10-K | Act ...Dec 1, 2022 · GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today the successful ... Applied Genetic Technologies Corporation (AGTC) reported positive 3-month interim data from its ongoing phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP).30 thg 11, 2022 ... Acompanhe a ação AGTC (Applied Genetic Technologies Corp.): gráficos, cotações, notícias e mais.Instagram:https://instagram. practice forex tradingrpdetf tanbest 401k provider Syncona to acquire Applied Genetic Technologies Corporation (AGTC) A newly established portfolio company of Syncona Limited will commence a tender offer to acquire all outstanding shares of AGTC for $0.34 per share, valuing AGTC at approximately $23.5 million (£20.8 million [1] ), plus the potential for up to an additional $50.0 million (up to ...GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage ... uto zonexpeng stocks Oct 24, 2022 · Applied Genetic Technologies Corp. is being taken private by healthcare company creator Syncona in a transaction that will keep the struggling gene therapy developer from running out of cash next year. Syncona will pay $0.34 per share, or about $23.5 million, for rights to the company, which is commonly known as AGTC. Invest in Applied Genetic Technologies - CVR, NASDAQ: AGTC.CNT - View real-time AGTC.CNT price charts. Online commission-free investing in Applied Genetic ... short term insurance washington state GAINESVILLE, Fla. and CAMBRIDGE, Mass. and LONDON , Oct. 26, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC) (“AGTC” or the “Company”) and a newly established portfolio company of Syncona Limited (“Syncona”), a leading healthcare company focused on founding, View HTML. PDF Version.Follow. Dublin, June 28, 2021 (GLOBE NEWSWIRE) -- The "Gene Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The ...Applied Genetic Technologies Corporation Contacts: IR Contact: David Carey Lazar FINN Partners T: (212) 867-1768 [email protected] Corporate Contact: Jonathan Lieber Chief Financial Officer Applied Genetic Technologies Corporation T: (617) 843-5778 [email protected]